ClinVar Miner

Submissions for variant NM_000303.3(PMM2):c.392del (p.Pro131fs) (rs1555449607)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000657181 SCV000778902 pathogenic not provided 2018-05-12 criteria provided, single submitter clinical testing The c.392delC variant in the PMM2 gene has been reported previously, using alternate nomenclature c.398_399delC, in one individual with CDG-1a, however, it is unknown if this individual harbored a second PMM2 variant (Matthijs et al., 2000). The c.392delC variant causes a frameshift starting with codon Proline 131, changes this amino acid to a Leucine residue, and creates a premature Stop codon at position 23 of the new reading frame, denoted p.Pro131LeufsX23. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The c.392delC variant is not observed in large population cohorts (Lek et al., 2016). We interpret c.392delC as a pathogenic variant.
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000657181 SCV000861541 pathogenic not provided 2018-05-25 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000781733 SCV000920012 likely pathogenic Congenital disorder of glycosylation, type Ia 2018-05-09 criteria provided, single submitter clinical testing Variant summary: PMM2 c.392delC (p.Pro131LeufsX23) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 31784 control chromosomes (ExAC). The variant, c.392delC, has been reported in the literature in at least one individual affected with Congenital Disorder of Glycosylation Type 1a (Matthijs_1999). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.